# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>WELCOME LETTER</td>
</tr>
<tr>
<td>5</td>
<td>MEMBER EXPERIENCE</td>
</tr>
<tr>
<td>8</td>
<td>INTRODUCING THE IASLC'S NEW CSO</td>
</tr>
<tr>
<td>10</td>
<td>EDUCATION AND EVENTS</td>
</tr>
<tr>
<td>12</td>
<td>WCLC 2019</td>
</tr>
<tr>
<td>14</td>
<td>SCIENTIFIC INITIATIVES</td>
</tr>
<tr>
<td>18</td>
<td>ADVOCACY</td>
</tr>
<tr>
<td>21</td>
<td>FINANCIALS</td>
</tr>
<tr>
<td>22</td>
<td>BOARD OF DIRECTORS AND STAFF</td>
</tr>
<tr>
<td>24</td>
<td>INTERNATIONAL LUNG CANCER (ILC) FOUNDATION</td>
</tr>
<tr>
<td>27</td>
<td>TOP 2019 SPONSORS</td>
</tr>
</tbody>
</table>
Dear Friends,

In this time of unprecedented change for the lung cancer field, we’ve been asking what our association can do to help facilitate further advances in lung cancer care – not to mention how can we become an even more effective partner for the communities we are dedicated to serving.

The answer? We must become more nimble, more responsive and more relational than ever before. And throughout 2019, our association has done just that.

With groundbreaking partnerships like the Lung Ambition Alliance, we set the ambitious goal of doubling five-year survival by focusing on solutions in screening and early detection, delivering innovative medicine and enhancing the quality of care. The IASLC Staging Project and Early Lung Imaging Confederation Project are foundational components of this bold initiative. By investing more in our staff and operations, we committed ourselves to improving the experience of our members and becoming more attuned to your diverse needs. Through leveraging the expertise of our member-based committees, we provided guidance on some of the most topical issues in lung health – including important position statements on tobacco control and e-cigarettes. In rebranding and relaunching our foundation as the International Lung Cancer Foundation, we have increased our ability to fund the most novel research. And finally, by streamlining and improving our meetings, we delivered unparalleled educational programs – which culminated in 2019 with record-setting attendance and submitted abstracts at our signature World Conference on Lung Cancer.

But we can’t stop there. In 2020, we reaffirm our efforts to meet the demands of this ever-changing field, offering new programs and participating in unique partnerships to empower the global lung cancer community to make inroads against this complex disease. The makeup of the IASLC’s leadership has also changed dramatically in the past few months. Our 2019 Board of Directors election brought many new faces to our leadership, while maintaining our commitment to being an international and multidisciplinary organization. We also hired the IASLC’s first Chief Science Officer, Dr. Chandra P. Belani, to further shape and guide our scientific agenda in this time of rapid change. With our strong board and dynamic staff, we are confident that the organization is well-equipped to meet the challenges and seize the opportunities of what lies ahead. This is especially true when you add the leadership and expertise of you, our incredible members!

And so, as we move into 2020, we want to thank you for your continued engagement with the IASLC and urge you to stay connected to us in the months ahead. Be sure to check out our website for the latest news. Follow us on social media. And consider joining us at one of our many upcoming educational and scientific meetings. But most importantly, please remain passionate about your work to advance lung cancer care. Whether you are a scientist, clinician, nurse, investigator or advocate, your contributions are of fundamental importance in improving clinical outcomes and quality of life for patients and their loved ones.

With each year that goes by, the science of lung cancer treatment advances in ways we previously thought impossible – driven by the hard work and dedication of the multidisciplinary lung cancer community. We are proud to be a partner, resource and home for this global coalition of professionals and look forward to many more collaborations, achievements and breakthroughs in the months to come.

Dr. Tetsuya Mitsudomi, IASLC President

Dave Mesko, IASLC Chief Executive Officer
MEMBERSHIP

An Innovative, Global Effort to Conquer Thoracic Cancers Worldwide

The IASLC’s global membership base is a driving force in the fight against lung cancer – leading groundbreaking research studies, authoring innovative papers and collaborating across disciplines and country lines in order to push science forward.

Throughout our more than 45-year history, the IASLC has been a platform, resource, partner and home to the lung cancer community, reaching nearly 9,000 members in 2019.

The IASLC has also – over the past year – worked collaboratively with its membership to make important contributions to the field. From providing guidance on e-cigarettes and liquid biopsy to organizing global meetings and gathering data for the next edition of the international staging system, we continue to successfully unite our diverse membership into a formidable movement dedicated to improving outcomes and inspiring hope for those affected by this difficult disease.
MEMBERSHIP BY PRIMARY SPECIALTY

- **MEDICAL ONCOLOGY** 2,843 Members (32.7%)
- **THORACIC SURGERY** 1,166 Members (13.4%)
- **PULMONARY MEDICINE** 925 Members (10.6%)
- **BASIC SCIENCE/RESEARCH** 1,120 Members (12.9%)
- **RADIATION ONCOLOGY** 585 Members (6.7%)
- **PATHOLOGY** 430 Members (4.9%)
- **DIAGNOSTIC RADIOLOGY** 144 Members (1.7%)
- **PHARMACY** 63 Members (0.7%)
- **BLANK** 22 Members (0.3%)
- **SMOKING CESSATION** 11 Members (0.1%)
- **PATIENT ADVOCACY** 278 Members (3.2%)
- **NURSING** 196 Members (2.3%)
- **BIOTECH/PHARMACEUTICAL INDUSTRY** 191 Members (2.2%)
- **STATISTICS** 82 Members (0.9%)
- **HEMATOLOGY** 30 Members (0.3%)
- **RESP THERAPY/PHYSIOTHERAPY** 7 Members (0.1%)
- **OTHER** 598 Members (6.9%)
- **OTHER** 0.7%
MEMBERSHIP BY PRIMARY LOCATION

ACADEMIC MEDICAL CENTER/UNIVERSITY
4,261 Members
49.0%

CANCER CENTER
1,722 Members
19.8%

OTHER
739 Members
8.5%

LABORATORY RESEARCH
159 Members
1.8%

PHARMACEUTICAL/BIOTECH
577 Members
6.6%

PRIVATE PRACTICE (OFFICE OR HOSPITAL)
542 Members
6.2%

NONPROFIT OR ADVOCACY
144 Members
1.7%

TRAINING PROGRAM
199 Members
2.4%

ADMINISTRATION
96 Members
1.1%

GOVERNMENT AGENCY
229 Members
2.6%

RETIRED
25 Members
0.3%
In November 2019, Chandra P. Belani, M.D. was named chief science officer (CSO) of the IASLC. As CSO, Dr. Belani will direct, guide and support the IASLC’s scientific strategy, including, but not limited to, scientific research projects, publications, educational content for conferences and educational offerings for members. His extensive experience, scientific acumen and notable leadership ability allows us to strengthen our educational programs, expand our scientific initiatives, solidify our relevance and deliver more value to our members, supporters and partners.

Dr. Belani is currently professor of Medicine in the Division of Hematology/Oncology in the Department of Medicine at the Penn State Hershey Medical Center in Hershey, PA. Dr. Belani also worked in several positions at the Penn State College of Medicine as deputy director of the Penn State Cancer Institute, associate director of Clinical Research and Director of the Lung Cancer Program.

Prior to that he served in multiple leadership positions at University of Pittsburgh Cancer Institute in Pittsburgh, PA, including director of Community Oncology, co-director of the Lung Cancer Program and co-director of the Experimental Therapeutics Program. His research accomplishments in the areas of lung cancer and new drug development have led to changes in treatment paradigms, and his therapeutic strategies have been approved and adopted as ‘standards of care’ for the management of lung cancer.

Dr. Belani has significant experience working with peer-reviewed oncology journals and has served as a consultant or advisor on multiple medicine and oncology journals—roles that will be valuable in coordinating the various scientific publications of the IASLC.

Dr. Belani is a graduate of Sawai Man Singh Medical College, University of Rajasthan, Jaipur, India. After completing his residency in internal medicine, he was a fellow in Hematology and Oncology at the University of Maryland from 1985 to 1988. He joined the faculty at the University of Maryland Cancer Center thereafter, and served as assistant professor of Medicine and Oncology, director, Thoracic Oncology at the University of Maryland Medical School in Baltimore. He is board certified by the American Board of Internal Medicine and the American Board of Internal Medicine Oncology, and holds memberships in the American Society of Clinical Oncology, American Association of Cancer Research and the IASLC.

“At the IASLC, the chief science officer position provides me with a unique opportunity to give, contribute and grow the organization. I am embarking on this challenge with the spirit of dedication, inspiration and motivation to improve the quality of the educational, research and scientific programs in collaboration with IASLC members worldwide,” Dr. Belani said. “In my role as CSO, I hope to develop a cohesive communications plan and ensure that the information released is consistent with the strategy at large, while working towards the ultimate goal of improving lung cancer outcomes.”
Dr. Chandra P. Belani, the IASLC’s new Chief Science Officer, at the IASLC’s Board of Directors Meeting with board member James Yang in December 2019.
A Primary Goal, A Global Focus

Education is at the core of the IASLC’s mission. It drives the organization forward, serving as a platform for global learning and collaboration in the fight to eradicate lung cancer and improve quality of life for those affected.

Our annual World Conference on Lung Cancer, regional meetings, digital webinars and hands-on workshops provide a unique forum for clinicians, investigators, advocates and patients from around the world to exchange ideas on topics ranging from the latest advances in the field to best practices for patient care. As a leader in the field of lung cancer, IASLC also produces a number of highly respected publications, including textbooks, atlases, manuals and resource materials.

IASLC 2019 CONFERENCES AND EVENTS

› IASLC 2019 Lung Cancer Targeted Therapies Meeting | Santa Monica, California
› IASLC 2019 Small Cell Lung Cancer Meeting | New York City, New York
› European Lung Cancer Congress 2019 | Geneva, Switzerland
› IASLC 2019 Mesothelioma Meeting | New York City, New York
› IASLC 2019 World Conference on Lung Cancer | Barcelona, Spain
› IASLC 2019 North America Conference on Lung Cancer | Chicago, Illinois
› IASLC 2019 Latin America Conference on Lung Cancer | Mexico City, Mexico
WCLC 2019

The World’s Largest Lung Cancer Conference Sets New Records

International, inclusive and iconic, the annual IASLC World Conference on Lung Cancer (WCLC) continues to set the bar for what a global medical conference can be. In 2019, the event broke records, with the conference drawing 7,755 delegates and 2,411 abstracts.

Presided over by Drs. Ramon Rami-Porta, Antoni Rosell and Enriqueta Felip, WCLC 2019 continued the association’s long-running tradition of delivering a rock-solid educational program marked by practice-changing abstracts with ample opportunities for networking with one’s peers, colleagues and friends. The conference also introduced an array of new programming – designed to meet the needs of a lung cancer community that is more diverse than ever before.

Some examples include: the IASLC’s inaugural STARS program, which brought aspiring patient research advocates to the WCLC for on-the-ground learning opportunities; highly-specialized workshops – focusing on topics ranging from cancer genomics to women’s experience in the thoracic oncology field; and the IASLC Road to Hope celebration, which featured the rebranding and relaunch of the IASLC Foundation as the International Lung Cancer Foundation.

WCLC EDUCATIONAL PROGRAMS: Educating the Next Generation

INTERNATIONAL MENTORSHIP PROGRAM:
A long-standing program dedicated to the principles of education, mentorship and collaboration, the IASLC’s International Mentorship Program is an initiative designed to turn today’s young researchers into tomorrow’s lung cancer leaders.

The program’s structure is two-fold. Each year’s participants are assigned well-established mentors who live and work in the region where the IASLC’s annual WCLC is taking place. Mentees initially meet their mentors on-site at the WCLC before traveling to their mentor’s home institution for a week to shadow them and learn more about their practice. During this shadowing period, program participants discuss their desired career path and interact with multidisciplinary cancer care teams.

The 2019 mentee class hailed from a diverse array of countries, including China, India, Indonesia, Namibia and Thailand.

IASLC ACADEMY:
Few things are as integral to the IASLC’s mission as helping support early-career physicians and researchers, which is why the IASLC Academy is one of the association’s most important WCLC-affiliated programs. The IASLC Academy is a two-year program open to medical school graduates focusing on thoracic cancer care. Those accepted into the Academy work closely with senior faculty: attending two WCLCs, honing their presentation skills and deepening their knowledge of multidisciplinary research in the process.

The most recent Academy participants include early career specialists from Argentina, Australia, Brazil, Canada, China, Egypt, India, Indonesia, Italy, Singapore, Switzerland and the United States of America.
WCLC 2019 AWARD WINNERS: Recognizing Excellence in the Lung Cancer Field

In addition to serving as a source for exceptional education, WCLC also represents an opportunity to recognize excellence in the field of lung cancer research. Each year, the association distributes several awards that recognize lifetime achievement in specific areas of practice, with the most significant honors – the IASLC Distinguished Awards – historically being distributed during the WCLC Opening Ceremony.

2019 PAUL A. BUNN, JR. SCIENTIFIC AWARD
Charles Rudin, MD, PhD, Sylvia Hassenfeld Professor and Chief of Thoracic Oncology, Memorial Sloan Kettering Cancer Center (MSKCC); Co-Director, Druckenmiller Center for Lung Cancer Research. New York, NY, United States.

2019 MARY J. MATTHEWS PATHOLOGY/TRANSLATIONAL RESEARCH AWARD
Andrew Nicholson, MD, PhD, Honorary Professor in Respiratory Pathology, National Heart and Lung Institute, Imperial College, London, United Kingdom.

2019 JOSEPH W. CULLEN PREVENTION/EARLY DETECTION AWARD
Denise R. Aberle, MD, Professor of Radiology and Bioengineering and Vice Chair for Research in Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, United States.

2019 MERIT AWARD
Hisao Asamura, MD, Professor of Surgery, Chief, Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan.

For more information on the IASLC’s Distinguished Award Winners, as well as its Advocacy and Travel Award Winners, and its IASLC Academy and Mentorship Program participants, please visit www.IASLC.org/about-iaslc/awards.

WCLC 2019 AWARD WINNERS: Recognizing Excellence in the Lung Cancer Field

In addition to serving as a source for exceptional education, WCLC also represents an opportunity to recognize excellence in the field of lung cancer research. Each year, the association distributes several awards that recognize lifetime achievement in specific areas of practice, with the most significant honors – the IASLC Distinguished Awards – historically being distributed during the WCLC Opening Ceremony.

2019 PAUL A. BUNN, JR. SCIENTIFIC AWARD
Charles Rudin, MD, PhD, Sylvia Hassenfeld Professor and Chief of Thoracic Oncology, Memorial Sloan Kettering Cancer Center (MSKCC); Co-Director, Druckenmiller Center for Lung Cancer Research. New York, NY, United States.

2019 MARY J. MATTHEWS PATHOLOGY/TRANSLATIONAL RESEARCH AWARD
Andrew Nicholson, MD, PhD, Honorary Professor in Respiratory Pathology, National Heart and Lung Institute, Imperial College, London, United Kingdom.

2019 JOSEPH W. CULLEN PREVENTION/EARLY DETECTION AWARD
Denise R. Aberle, MD, Professor of Radiology and Bioengineering and Vice Chair for Research in Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, United States.

2019 MERIT AWARD
Hisao Asamura, MD, Professor of Surgery, Chief, Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan.

For more information on the IASLC’s Distinguished Award Winners, as well as its Advocacy and Travel Award Winners, and its IASLC Academy and Mentorship Program participants, please visit www.IASLC.org/about-iaslc/awards.
SCIENTIFIC INITIATIVES

Improving Lung Cancer Staging through International Collaboration

For more than 20 years, the IASLC Lung Cancer Staging Project has provided valuable recommendations for the TNM classification of lung cancer – jointly published by the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC). The association is currently gathering data to inform the 9th edition of the TNM staging system, and as of November 2019, has collected the following number of cases from over 20 countries:

- **42,318** LUNG CANCER CASES
- **87** MESOTHELIOMA CASES
- **5,162** THYMIC CANCER CASES

For more information on the IASLC’s Staging Project or how to contribute data, please visit www.IASLC.org/staging.

A Fruitful Partnership to Optimize Brazilian Health Care

In 2019, the IASLC began a new collaboration with ASCO Quality Oncology Practice Initiative (QOPI®) to improve the quality of health care in Brazil. QOPI® is ASCO’s flagship quality program designed for outpatient-oncology practices to foster a culture of self-examination and improvement. The IASLC, in collaboration with ASCO, developed an IASLC lung track in QOPI® to focus on thoracic oncology health care. In 2020, the association will work to sign up practices within the Brazil region, helping institutions optimize the care they provide and improve outcomes.

SPOTLIGHT ON TOBACCO CONTROL AND SMOKING CESSATION.

Throughout 2019, the IASLC took specific and concentrated action regarding tobacco control and smoking cessation, lending its expertise to some of the most relevant and pressing issues of the day.

In order to address the IASLC’s position on electronic cigarettes, the IASLC’s Tobacco Control and Smoking Cessation Committee released a policy statement dedicated to providing clarity and the IASLC’s position in the complex landscape.

The statement advises that electronic cigarettes should never be used by youth or by adults who are not currently smoking, and that evidence-based cessation remains the best method for effective and safe cessation.

Additionally, in late-2019 the IASLC released an official Declaration written to draw attention to the potentially detrimental effects of continuing to smoke following a cancer diagnosis and how smoking cessation following a diagnosis can improve patient outcomes.

The Declaration’s recommendations focus on several key areas – from advocating for universal screening for tobacco use and greater smoking cessation education for patients and their families to calls for the incorporation of screening for tobacco use in clinical trials and analysis of results to better understand patient outcomes.

Read the full text of the policy statement and declaration at IASLC.org/ecigarettes or IASLC.org/tobaccodeclaration.
The **LungAmbition Alliance**

CHANGING THE PACE OF PROGRESS IN LUNG CANCER SURVIVAL

The Lung Ambition Alliance is an alliance of the world’s top oncology minds to change the pace of progress in lung cancer survival. True to its name, the Alliance’s primary goal is to eliminate lung cancer as a cause of death – with its first, ambitious step being to double five-year survival by 2025.

The Alliance aims to accelerate advances and improve survival by focusing on three key areas:

- **Screen and Diagnose Early**
- **Deliver Innovative Medicine**
- **Enhance the Quality of Care**

The Lung Ambition Alliance includes flagship projects:

- **EARLY IMAGING LUNG CONFEDERATION (ELIC)**: A new cloud-based, IASLC-owned global screening registry designed to improve the multidisciplinary detection and management of early stage lung cancer when there is still potential for a cure.

- **THE MAJOR PATHOLOGIC RESPONSE PROJECT**: The Alliance is working to validate surrogate endpoints and identify predictive biomarkers, with the goal of accelerating the development of next-generation treatments.

- **ILC²: INITIATIVES IN LUNG CANCER CARE**: The ILC² program invites patient and caregiver nonprofit organizations to submit project proposals that can potentially transform patient care in countries around the world.

Together, we can break through limits.

---

**IASLC MOLECULAR TESTING SURVEY: UNDERSTANDING GLOBAL BARRIERS TO OPTIMAL THERAPY**

Testing patients with lung cancer for molecular driver mutations can often assist with optimizing care and improving outcomes. However, sizable barriers seem to exist that impede global implementation of molecular testing. In order to better understand the global molecular testing landscape, as well as to begin formulating potential strategies for overcoming regional barriers, the IASLC conducted a global survey to evaluate perceptions of molecular testing in lung cancer – specifically regarding testing frequency, current practice and barriers. Receiving over 2,500 responses from more than 100 countries, the association gleaned the following:

- Many respondents are not satisfied with the state of molecular testing
- One third of respondents were unaware of the most recent, evidence-based guidelines
- The top five barriers included: time, awareness, access, quality and cost
- Continuous education around molecular testing should be intensified on national and international levels to ensure patients receive optimal therapy

Results were shared at three of the IASLC’s 2019 meetings, with each presentation tailored to focus specifically on the relevant region, and will be published in the *Journal of Thoracic Oncology*.

**IASLC MPR PAPER: “IMPROVING CONSISTENCY OF PATHOLOGIC ASSESSMENT OF TREATMENT RESPONSE”**

Based on a substantive literature review and the opinion of 41 expert IASLC members, the *IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapy* is a paper intended to inform good clinical practice, both in and outside of clinical trials, with the goal ultimately being to improve consistency of pathologic assessment of treatment response.

In late 2019, the IASLC opened this important manuscript to public comment. During this time, dozens of comments were recorded. In the new year, the association will seek to conduct an interobserver reproducibility study based on recommendations, as well as collect data to compare pathologic response and other biomarkers to disease-free and overall survival.
Serving the Lung Cancer Community Through Cutting Edge Publications

JOURNAL OF THORACIC ONCOLOGY (JTO)

Over the past few years, the Journal of Thoracic Oncology (JTO), the IASLC’s official journal, has become the field’s authoritative publication for education and information related to all aspects of thoracic malignancies. The JTO includes original research, reviews and opinion pieces, and reaches a diverse audience, including epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians and research scientists with a special interest in thoracic oncology.

For evidence of the JTO’s rise in influence and authority, one only needs to look at its impact factor, which has climbed dramatically in recent years. From having an impact factor of 6.595 in 2016, the JTO’s impact factor rose in a meteoric fashion to 10.336 in 2017 and then again to 12.460 in 2018. Additionally, it now ranks 10th out of all oncology journals and 3rd out of all respiratory system publications.
JTO CLINICAL AND RESEARCH REPORTS (JTO CRR)

At the 2019 World Conference on Lung Cancer, the IASLC and the JTO editorial team announced the launch of a new journal to incorporate the wealth of submitted manuscripts that the journal is currently unable to publish due to space limitations. This new journal, entitled the *JTO Clinical and Research Reports* (JTO CRR), launched in 2020. It aims to complement the JTO by offering authors a gold open access publication option.

For more information on the JTO CRR, please visit [www.JTOCRR.org](http://www.JTOCRR.org).

“With this new impact factor, the JTO is now among the top 10 oncology journals and a leading journal in thoracic oncology. This achievement is a testament to the strong editorial team, which helps to handle manuscripts quickly; the IASLC, which supports the JTO’s mission; and the support of the thoracic oncology and clinical and research community.”

-Dr. Alex Adjei, Editor-in-Chief-
In 2019, the association launched a new program: Supportive Training for Advocates in Research and Science (STARS).

Designed to develop lung cancer patient research advocates (PRAs), STARS equips budding PRAs to better communicate complex science to their patient organizations and contribute their unique perspectives in matters of lung cancer research and policy. The inaugural year included five aspiring PRAs, who were each paired with a mentor and received training on the fundamentals of lung cancer science and patient advocacy. The program culminated with both patients and mentors attending the IASLC’s 2019 World Conference on Lung Cancer in Barcelona and giving a series of presentations on individually selected focus topics.

**The 2019 STARS Cohort Included:**

- Caleb Egwuenu | Nigeria | Mentor: Upal Basu-Roy | Focus: Small Cell Lung Cancer
- Shelly Engfer-Triebenbach | USA | Mentor: Dusty Donaldson | Focus: Clinical Trials
- Laura Greco | USA | Mentor: Jill Feldman | Focus: Targeted Therapies
- Kim MacIntosh | Canada | Mentor: Jill Hamer-Wilson | Focus: Biomarkers
- Susan McCullough | Australia | Mentor: Lillian Leigh | Focus: Clinical Trials
Lung Cancer Awareness Month Coalition 2019:
UNITING A COMMUNITY’S VOICE

For the past four years, the IASLC has been at the forefront of the Lung Cancer Awareness Month Coalition - a unique, multinational coalition that aims to raise awareness and dispel stigma each November during Lung Cancer Awareness Month.

Composed of over 50 leading research and advocacy organizations, the Coalition seeks to accomplish its goals by promoting patient stories, lung cancer facts and treatment resources through a combination of digital, traditional and social media. Additionally, the Coalition has developed and disseminated its own resources in the form of patient/provider cards. And finally, throughout the month, it hosts a series of live events geared toward promoting acceptance, establishing solidarity and increasing available research funding.

All of these efforts are organized through the Coalition’s official website, www.LCAM.org, which acts as a hub for its annual work and a tool to unite and augment the voice of the global lung cancer community.

LCAM Sponsors:

Bristol-Myers Squibb
Lilly Oncology
Novartis
Genentech
A Member of the Roche Group
Each year, the IASLC offers travel awards to highly qualified patient advocates to help them attend its annual World Conference on Lung Cancer at no cost. These awards help unite the global lung cancer community, connecting advocates to investigators and clinicians, and providing a platform for advocates to share their unique perspective.

Paul Brown | Australia

Weini Qiu | China

Gina Hollenbeck | United States

Csaba Laszlo Degi | Romania

Christine Qiong Wu | Canada
## FINANCIALS

### December 31 (Unaudited)

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Assets</strong></td>
<td>$19,713,657</td>
<td>$18,206,150</td>
</tr>
<tr>
<td><strong>Liabilities</strong></td>
<td>$5,285,024</td>
<td>$4,276,746</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td>$14,428,633</td>
<td>$13,929,403</td>
</tr>
</tbody>
</table>

### Program Revenues

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Revenues</td>
<td>$15,750,908</td>
<td>$13,551,881</td>
</tr>
<tr>
<td>Membership Revenue</td>
<td>$835,116</td>
<td>$763,425</td>
</tr>
<tr>
<td>Other Revenue</td>
<td>$59,584</td>
<td>$10,271</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$16,645,608</td>
<td>$14,325,577</td>
</tr>
</tbody>
</table>

### Direct Program Expenses

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct Program Expenses</td>
<td>$12,083,461</td>
<td>$10,443,009</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$16,860,800</td>
<td>$14,385,962</td>
</tr>
</tbody>
</table>

### Operating (Deficit)

<table>
<thead>
<tr>
<th></th>
<th>2019 ($215,192)</th>
<th>2018 ($60,386)</th>
</tr>
</thead>
</table>

### Other Income/Expense

<table>
<thead>
<tr>
<th></th>
<th>2019 $714,422</th>
<th>2018 ($409,516)</th>
</tr>
</thead>
</table>

### Change in Net Assets

<table>
<thead>
<tr>
<th></th>
<th>2019 $499,230</th>
<th>2018 ($469,902)</th>
</tr>
</thead>
</table>

### 2019 REVENUE

- **Conferences & Meetings**: 74%
- **Scientific Projects**: 11%
- **Publications Projects**: 8%
- **Membership 2019**: 5%
- **Patient Advocacy**: 2%
2019-2021 BOARD OF DIRECTORS

BOARD OFFICERS:
President: Tetsuya Mitsudomi | Japan
President-Elect: Heather Wakelee | United States
Past-President: Giorgio Scagliotti | Italy
Treasurer: Suresh Ramalingam | United States
Secretary: Enriqueta Felip | Spain
Chief Executive Officer: Dave Mesko | United States

BOARD MEMBERS:
Andrea Bezjak | Canada
Julie Brahmer | United States
Anne Fraser | New Zealand
Roy Herbst | United States
Clarissa Mathias | Brazil
Yuko Nakayama | Japan
Masayuki Noguchi | Japan
Nir Peled | Israel
Erik Thunnissen | The Netherlands
Paul Van Schil | Belgium
James Yang | Taiwan
Caicun Zhou | China

IASLC STAFF:
Tessa Baxter, Foundation Coordinator
Chandra P. Belani, Chief Science Officer
Kirsten Black, Educational Programs Manager
Becky Bunn, Director of Strategic Initiatives
Jill Daigneault, Scientific Affairs Project Manager
Kathy Doherty, Director of Human Resources
Ken Harrell, Member Records Administrator
Kristin Ito, Associate Director, ILC Foundation and Patient Advocacy
Stephanie Lenhart, Accounting Manager
Sara Lindsey, Administrative Assistant
Jan Mazotti, Associate Director, Communications and Marketing
Dave Mesko, Chief Executive Officer
Abigail Metzger, Corporate Relations Coordinator
Adam Mohrbacher, Communications and Marketing Manager
Karen Muth, Executive Assistant and Board Liaison
AnnMarie Priest, Chief Development Officer; Executive Director, ILC Foundation
Kristin Richeimer, Chief Experience Officer
John Skadow, Chief Financial Officer
Jeanette Stensgaard, Conference Planning Manager
Mary Todd, Managing Editor, Journal of Thoracic Oncology and JTO Clinical and Research Reports
Jacinta Wiens, Associate Director of Scientific Affairs
Kelsey Wood, Associate Director, Member Experience
Murry Wynes, Senior Advisor, Scientific Affairs
Kexin Yu, Accountant
We thank our outgoing board members who completed their service in 2019. From left to right, Drs. Seto, Pirker, Satouchi, Carbone, Boyer, Ikeda and Reck.

The IASLC’s leadership team. From left to right, Dr. Tetsuya Mitsudomi (President), Dr. Giorgio Scagliotti (Past-President), Dr. Heather Wakelee (President-Elect) and Dave Mesko (CEO).
At the 2019 World Conference on Lung Cancer in Barcelona, Spain, the IASLC unveiled the International Lung Cancer Foundation (ILC Foundation) to the global lung cancer community – its relaunched and rebranded foundation.

The relaunch of the IASLC’s foundation was the culmination of a multi-year process to transition the former IASLC Foundation from an IASLC department to a stand-alone 501(c)(3) public charity. Along with its new name, the rebranding initiative included the development of a new logo, color scheme, brand guidelines and powerful tagline: “Inspiring hope through research.”

In 2019, the ILC Foundation lived up to that promise, awarding 11 fellowships and young investigator awards that totaled more than $1 million. The 2019 fellowship and award recipients span the globe, working in Australia, Italy, the Netherlands and the USA on projects that will significantly contribute to lung cancer research and treatment improvements for patients worldwide.

Of course, no single organization can provide the level of funding necessary for a health problem that is as large and challenging as lung cancer. Therefore, in 2019, the ILC Foundation partnered with several like-minded organizations to award joint grants and make an even more substantial impact in the field of lung cancer research.

Partnering organizations include:
The ILC Foundation Young Investigator award has been a terrific vote of confidence, not only for an early career clinician researcher, but more importantly for the multidisciplinary team I am part of at Concord Cancer Centre at Concord Hospital, Sydney. Our priority is to provide free, world class cancer survivorship care to patients. Recognition of our efforts with a grant from a prestigious international organization such as ILCF is validation that we are on track to do more for patients with lung cancer.”

-Dr. Ashanya Malalasekera
ILC Foundation Young Investigator 2019-2020
International Lung Cancer Foundation 2019 Donors

$10,000+
AstraZeneca

$5,000-$9,999
Addario Lung Cancer Medical Institute
Biodesix
David and Diane Gandara
The Estate of Adi Gazdar
GO2 Foundation for Lung Cancer
Xcovery
Li Xu

$1,000-$4,999
Alex Adjei
Paul Bunn, Jr.
David Paul Carbone
Davis Graham & Stubbs, LLP
Lauren Fisher
Norihiko Ikeda
International Conference Services (ICS)
Lung Cancer Foundation of America (LCFA)
LUNGevity
Tetsuya Mitsudomi
Tony Shu Kam Mok
Yuko Nakayama
AnnMarie Priest
Miyako Satouchi
Takashi Seto
Charles and Jean Townsend
Heather Wakelee

$500-$999
Alain Borczuk
Michael Boyer
Julie Brahmer
Suresh Ramalingam
David Spigel
Thomas Suby-Long
Anne Tsao

UP TO $499
Tariqa Ackbarali
Charu Aggarwal
Ryosuke Amemiya
David Ball
Kristina Barsketis
Tessa Baxter
Kirk and Linda Bell
Peter Berzince
Ted Blank
Becky Bunn
Andre Caldas
Andrew Chung
Christian Couture
Martin Edelman
John Edwards
Rosana Eisenberg
Charles Feng
Edie and Daniel Garcia
David Gininger
Rui Haddad
Peter Hansen
Karen Hayden
David Felix Heigener
Jody Herrmann
Brent Hilvitz
Susan Hocker
William C. & Phyllis Hocker
Jeannette Hood
Peter Illei

Dani Janklow
Ryu Kanzaki
Jiro Kawashima
Yeon Wook Kim
Choon-Taek Lee
Zhongxing Liao
ULTRASPEX LLC
Innovest Portfolio Solutions LLC
Claudia Lorge
Erik MacLaren
Eldsamira Mascarenhas
Clarissa Mathias
Heidi Mulqueen
Reginald Munden
Calvin Newton
Kerst Oselin
James Pantelas
Jason Peck
Emily Petoskey
Emily Pujals
Luis Raez
Martin Reck
Noemi Reguart
Kristin Richeimer
Sergio Santillana
Lucianno Santos
Tomonari Sasaki
Navneet Singh
John Skadow
David Spigel
Motohiro Tamiya
Lindsay Thompson
Qing Tian
Mary Todd
Paul Van Schil
William Walsh
C. Dave Wines
Hiromasa Yamamoto
Milada Zemanova
TOP SPONSORS OF 2019

AstraZeneca
MERCK
Genentech
A Member of the Roche Group
Roche
Bristol-Myers Squibb
AMGEN
Lilly
Boehringer Ingelheim
BAYER
Takeda
NOVARTIS
Daiichi-Sankyo